PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
开发用于抗肿瘤疫苗 CaTeVac 临床前研究的动物源同源细胞产品的方案
英文原题：Development of a Protocol for Obtaining a Homologous Cell Product of Animal Origin Intended for Preclinical Studies of Antitumor Vaccine CaTeVac.
查看英文原题
Development of a Protocol for Obtaining a Homologous Cell Product of Animal Origin Intended for Preclinical Studies of Antitumor Vaccine CaTeVac.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在开发用于癌症患者过继性免疫治疗的人类细胞药物临床前研究方案时，其生物学效应应通过描述其免疫学作用的数据加以证实。将人类自体树突状细胞疫苗给予免疫功能健全的动物并进行研究，在免疫相容性方面并不充分。可以使用免疫功能低下、基因敲除或转基因动物，或者获取同源细胞产品，即基于动物细胞、采用与获取原始人类临床实践制剂相似技术制备的制剂。在本研究框架内，我们按照与获取人类疫苗树突状细胞相似的技术，制定了基于动物树突状细胞（小鼠、大鼠）获取同源细胞产品的方案，并证明了动物（小鼠）与人类树突状细胞的形态学特征及分化抗原（CD11c、CD80、CD86和CD83）表达具有可比性。
展开英文摘要原文
When developing a program of preclinical studies of human cell-based drugs intended for adoptive immunotherapy of cancer patients, the biological effect should be substantiated by data describing their immunological action. Administration and study of human autologous dendritic cell vaccine to immunocompetent animals are not adequate in terms of immunological compatibility. It is possible to use immunocompromised, knockout, or transgenic animals or to obtain a homologous cellular product, namely, a preparation based on animal cells using a technology similar to obtaining the original preparation for clinical practice in humans.
Within the framework of this study, we have developed a protocol for obtaining a homologous cell product based on animal dendritic cells (mice, rats) according to a similar technology for obtaining human vaccine dendritic cells, and demonstrated the comparability of morphological characteristics and expression of differentiation antigens of dendritic cells (CD11c, CD80, CD86, and CD83) of animals (mice) and humans.
论文信息
- 作者
- Nekhaeva TL、Laskov ID、Fedoros EI、Danilova AB、Efremova NA、Emelyanova NV、Blokhina ML、Grigoryevskaya AV
- 单位
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia. nehaevat151274@mail.ru.Russia
- 期刊
- Bulletin of experimental biology and medicine2024 Apr
- 原文标识
- PubMed 38907062 · DOI 10.1007/s10517-024-06113-z